Funding to fight malaria falls $2 billion short of WHO target, study shows
April 26, 2019Medical Communications WHO, developing countires, funding, health economics, infectious diseases, malaria
Global spending on the fight against malaria has stalled, falling $2 billion short of World Health Organization (WHO) targets, according …
Researchers find Achilles’ heel protein in leukaemia
April 26, 2019Medical Communications AML, Edinburgh, Protein, YTHDF2, blood cancer, drug targets, leukaemia
An international team of researchers have identified an “Achilles’ heel” protein that could lead to the development of novel treatments …
FDA approves Beximco’s generic version of MSD’s allergy drug Periactin
April 25, 2019Sales and Marketing FDA, MSD, Periactin, allergy, generics, pharma
Bangladesh-based Beximco Pharma is celebrating following the decision from the FDA to approve its generic version of MSD’s antihistamine therapy …
Pharmacists should review care homes residents’ medicine regimens to reduce polypharmacy
April 25, 2019Medical Communications care homes, older people, pharmacists, pharmacy, polypharmacy
Pharmacists should review older people’s medicines regimens in order to reduce inappropriate polypharmacy, according to the Royal Pharmaceutical Society (RPS). …
ICR calls for faster access to innovative cancer drugs
April 25, 2019Medical Communications, Research and Development, Sales and Marketing Cancer, ICR, R&D, access, cancer drugs, incentives, innovation, oncology, pricing
The Institute of Cancer Research (ICR) has called for faster access to innovative cancer drugs in the UK. The call …
Interactions with the Agencies During Drug Development
April 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cambridge, NDA, drug development
NDA would like to invite you to join Professor Steffen Thirstrup, Director NDA Advisory Board, formerly Division Head at the Danish Medicines …
Senior GSK exec Richard Saynor revealed as new Sandoz CEO
April 25, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, Sandoz, appointment, pharma
Novartis has seen a major leadership change within its business, as the company announced that senior GlaxoSmithKline exec Richard Saynor …
Heart drugs show promise in stroke and dementia
April 25, 2019Research and Development angina, cilostazol, dementia, heart drugs, isosorbide mononitrate, stroke
Drugs for heart disease and angina have shown promise as preventative treatments for stroke and dementia, according to scientists from …
Pharma boosts lobby spending in first quarter of 2019
April 24, 2019Research and Development PhRMA, Trump, USA, congress, lobbying, lobbyists, pharma
The Pharmaceutical Research and Manufacturers of America (PhRMA) trade lobbyists have spent near record levels on lobbying in the first …
Working Life: Dr Todd Hobbs, Vice President and Chief Medical Officer, Novo Nordisk
April 24, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, Working Life, feature, pharma
Novo Nordisk’s VP and CMO discusses his leap from family medicine into the pharma industry, his biggest achievements, and how …
AbbVie’s Skyrizi snatches up FDA approval in moderate to severe plaque psoriasis
April 24, 2019Research and Development, Sales and Marketing AbbVie, FDA, Skyrizi, US, pharma, psoriasis
AbbVie has revealed that its interleukin-23 (IL-23) inhibitor Skyrizi (risankizumab-rzaa) has received marketing authorisation in the US from the FDA …
Eli Lilly sell Chinese rights to two antibiotics in deal worth $375 million
April 24, 2019Research and Development
US firm Eli Lilly has agreed to sell the Chinese rights to two of its antibiotics, Ceclor (cefaclor) and Vancocin …
Former pharma wholesaler execs face criminal charges over opioid crisis
April 24, 2019Research and Development Litigation, RDC, Rochester Drug Cooperative, opioid crisis, opioids
Laurence Doud III, the former CEO of New York-based Rochester Drug Co-operative (RDC) – one of the largest drug distributors …
Teva terminates Ajovy at Phase 3 in episodic cluster headache
April 24, 2019Research and Development Teva, ajovy, headache, pharma
Israeli pharmaceutical firm Teva has announced its intention to terminate further development of its calcitonin gene-related peptide (CGRP) inhibitor Ajovy …
Keytruda/Inlyta combo scores FDA approval in advanced kidney cancer
April 23, 2019Manufacturing and Production, Sales and Marketing FDA, MSD, Pfizer, Sutent, inlyta, keytruda, pharma
MSD’s anti-PD-1 therapy Keytruda (pembrolizumab) has secured another approval from the FDA, this time as a first-line treatment in combination …
J&J pay $9.9 million to settle surgical mesh implant case
April 23, 2019Manufacturing and Production . Johnson & Johnson, J&J, JJ, Johnson & Johnson, Litigation, washington
Healthcare conglomerate Johnson & Johnson has agreed to pay $9.9 million to settle a Washington state lawsuit over the firm’s …
Pfizer immune-oncology leader joins Aduro Biotech as new CMO
April 23, 2019Manufacturing and Production Aduro Biotech, Cancer, Pfizer, immuno-oncology, immunotherapy, oncology
Pfizer’s vice president and head of immune-oncology clinical development has joined Aduro Biotech as the company’s new Chief Medical Officer, …
Signal boosting implant allows patients with Parkinson’s to walk
April 23, 2019Manufacturing and Production Canada, Parkinson's, Western University, electrical signals, implant
Patients with Parkinson’s have been able to walk after receiving electrical stimulation to their spines. A new treatment, developed by …
Innovative malaria vaccine to be trialled in Malawi
April 23, 2019Manufacturing and Production GSK, Mosquirix, RTS S, ghana, kenya, malaria, malawi
An innovative malaria vaccine is set to be trialled in Malawi as part of large scale trials which will see …
Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy
April 18, 2019Research and Development Novartis, Zolgensma, pharma
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene …
Latest content
Scots neonatal innovations target hearing loss and earlier care
Agentis Health Group acquires Clinical Pharmacist Solutions
